The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CAPELA: A phase II multicenter open-label randomized study of capecitabine in combination with elacestrant versus capecitabine alone in advanced estrogen receptor (ER)–positive breast cancer (TBCRC 070).
 
Kristina Fanucci
No Relationships to Disclose
 
Tianyu Li
No Relationships to Disclose
 
Michelle DeMeo
No Relationships to Disclose
 
Emma Kelly
No Relationships to Disclose
 
Sara Tolaney
Consulting or Advisory Role - AADi; Aktis Oncology; Ambrx; Arvinas; AstraZeneca; Avenzo Therapeutics; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Boehringer Ingelheim; Boundless Bio; Bristol-Myers Squibb; Celcuity; Circle Pharma; Corcept Therapeutics; Cullinan Oncology; Daiichi Sankyo; Denali Therapeutics; eFFECTOR Therapeutics; Eisai; Ellipses Pharma; Genentech; Immunomedics/Gilead; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Novartis; Olema Pharmaceuticals; Pfizer; Reveal Genomics; Samsung Bioepis; Seagen; Summit Therapeutics; Systimmune; Tempus; Zuellig Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; AstraZeneca; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Erica Mayer
Consulting or Advisory Role - AstraZeneca; Atkis; Genentech; Lilly; Novartis
 
Nabihah Tayob
No Relationships to Disclose
 
Antonio Wolff
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Ian Krop
Employment - DiaMedica (I); PureTech (I)
Leadership - DiaMedica (I); PureTech (I)
Stock and Other Ownership Interests - DiaMedica (I); PureTech (I)
Honoraria - AstraZeneca; Daiichi Sankyo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; EMD Serono; Genentech/Roche; Merck; Merck KGaA; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - anti-murine CD19 monoclonal antibody licensed to PharMingen
 
Rinath Jeselsohn
Consulting or Advisory Role - AstraZeneca; Carrick Therapeutics; Lilly; Novartis; Pfizer
Research Funding - Lilly; Novartis; Pfizer; Recursion Pharmaceuticals (Inst)